Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Accounts Payables: 2011-2025

Historic Accounts Payables for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2025 value amounting to $835,000.

  • RedHill Biopharma's Accounts Payables fell 56.33% to $835,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $835,000, marking a year-over-year decrease of 56.33%. This contributed to the annual value of $1.2 million for FY2024, which is 64.37% down from last year.
  • Latest data reveals that RedHill Biopharma reported Accounts Payables of $835,000 as of Q2 2025, which was down 28.51% from $1.2 million recorded in Q4 2024.
  • RedHill Biopharma's Accounts Payables' 5-year high stood at $15.2 million during Q3 2021, with a 5-year trough of $835,000 in Q2 2025.
  • Moreover, its 3-year median value for Accounts Payables was $2.5 million (2023), whereas its average is $2.4 million.
  • As far as peak fluctuations go, RedHill Biopharma's Accounts Payables surged by 150.68% in 2021, and later slumped by 68.62% in 2022.
  • Over the past 5 years, RedHill Biopharma's Accounts Payables (Quarterly) stood at $11.7 million in 2021, then tumbled by 63.73% to $4.2 million in 2022, then declined by 22.51% to $3.3 million in 2023, then plummeted by 64.37% to $1.2 million in 2024, then plummeted by 56.33% to $835,000 in 2025.
  • Its last three reported values are $835,000 in Q2 2025, $1.2 million for Q4 2024, and $1.9 million during Q2 2024.